Bioelectronics Corp (BIEL)

[DDGUY]

$$$$$==BIEL DD POSTED 02/22/14 UPDATED==$$$$$


TOO many to list but here are some accomplishments /(GAME CHANGERS)
===== Patent Approval MAY/2013
===== FDA Reclassification 02/2014
===== Innovation award 2014 (Sponsored by Oxford Pharmascience Group)
===== Products in http://www.boots-uk.com/ (stores and online)12/2013

= Holding 3 million for at least .05-.10 range, GLTA
Now I have a feeling institutional investors are over looking the products and the FDA update over the weekend and weeks ahead, IF they start buying which is normally transaction above $1 to $50million range who knows how far this will go...

I don't think people understand yet the value of share here, FDA not only changed the guidelines on BIELs clinical data but in return confirmed that there is evidence that this product is SAFE and the clinical evidence that it is effective,,, to back the FDA reclassification decision...

When your typical consumer wants to buy something, this reassurance that this is a proven product not just because the company says it works, but also it was proven to the FDA and the FDA feels its safe/efficient to be SOLD OTC, has a massive impact .... BIEL will probably get approached for a BUY OUT or massive funding for preferred shares, anyone in the right mind knows where this is going and they want in NOW...

they have more than one patented product even 1million sales of Allay which is proven to work for 70+% of women = $29million you add the other products in the USA this baby could do over $100million in sales on a conservative level ... FDA was a blessing for the company GLTA based on this you could say .30+ by 12/2014....

__________________________________________________________________
The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque. Our products caught the attention of several interested parties including three of Europe’s largest pharmaceutical companies. We are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company. The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agreements with royalty income. This strategy maintains our first-to-market advantage while giving us access to a good income stream and marketing power and access to capital (without further dilution). Another advantage would be the spill-over affect associated with this co-branding alliance on our other brands and obtaining additional distribution in other regions. http://www.bielcorp.com/investors/letter-from-the-president/

2014 Oxford Pharmascience Group (OXP) is sponsoring BIEL http://www.oxfordpharmascience.com/content/investors/share_price.asp

Park Lane Hotel, Piccadilly, London
Thursday, 6th March 2014
http://www.otc-bulletin.com/awards/pdfs/Nominations-Supplement-2014.pdf



____________________________________________________________________

Patents:::: https://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Bioelectronics+Corp.%22

IF YOU LIKE THE REDZONE CLICK HERE
http://investorshub.advfn.com/boards/addPersonMrk.asp?user=205909